Stock Track | Kymera Therapeutics Soars 5.04% Intraday as Analysts Maintain Bullish Ratings Despite Q4 Miss

Stock Track

Feb 27

Kymera Therapeutics Inc. (KYMR) saw its stock price surge 5.04% during intraday trading on Thursday, marking a significant rebound in the session.

The rally comes despite the company reporting a wider-than-expected fourth-quarter net loss and revenue that fell short of analyst estimates. However, investor sentiment appeared buoyed by continued analyst confidence and positive updates on the company's clinical pipeline.

Analysts at BTIG and Piper Sandler maintained their Buy and Overweight ratings on the stock, respectively, signaling ongoing belief in the company's long-term prospects. This support likely helped counter the negative initial reaction to the financial results. Furthermore, the company published a corporate presentation detailing progress in its pipeline of oral degrader medicines for immunology, including its lead STAT6 degrader, KT-621, which is in Phase 2b trials for atopic dermatitis and asthma.

The company's business update also highlighted a strong financial position, with $1.6 billion in cash providing a runway into 2029, allowing it to fund operations beyond several key clinical milestones.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1123725701"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1123725701\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1123725701?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 04:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123725701","market":"sg","top_or_hot":-1,"title":"Stock Track | Kymera Therapeutics Soars 5.04% Intraday as Analysts Maintain Bullish Ratings Despite Q4 Miss","media":"Stock Track","content":"<p>Kymera Therapeutics Inc. (KYMR) saw its stock price surge 5.04% during intraday trading on Thursday, marking a significant rebound in the session.</p><p>The rally comes despite the company reporting a wider-than-expected fourth-quarter net loss and revenue that fell short of analyst estimates. However, investor sentiment appeared buoyed by continued analyst confidence and positive updates on the company's clinical pipeline.</p><p>Analysts at BTIG and Piper Sandler maintained their Buy and Overweight ratings on the stock, respectively, signaling ongoing belief in the company's long-term prospects. This support likely helped counter the negative initial reaction to the financial results. Furthermore, the company published a corporate presentation detailing progress in its pipeline of oral degrader medicines for immunology, including its lead STAT6 degrader, KT-621, which is in Phase 2b trials for atopic dermatitis and asthma.</p><p>The company's business update also highlighted a strong financial position, with $1.6 billion in cash providing a runway into 2029, allowing it to fund operations beyond several key clinical milestones.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Kymera Therapeutics Soars 5.04% Intraday as Analysts Maintain Bullish Ratings Despite Q4 Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Kymera Therapeutics Soars 5.04% Intraday as Analysts Maintain Bullish Ratings Despite Q4 Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-27 04:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Kymera Therapeutics Inc. (KYMR) saw its stock price surge 5.04% during intraday trading on Thursday, marking a significant rebound in the session.</p><p>The rally comes despite the company reporting a wider-than-expected fourth-quarter net loss and revenue that fell short of analyst estimates. However, investor sentiment appeared buoyed by continued analyst confidence and positive updates on the company's clinical pipeline.</p><p>Analysts at BTIG and Piper Sandler maintained their Buy and Overweight ratings on the stock, respectively, signaling ongoing belief in the company's long-term prospects. This support likely helped counter the negative initial reaction to the financial results. Furthermore, the company published a corporate presentation detailing progress in its pipeline of oral degrader medicines for immunology, including its lead STAT6 degrader, KT-621, which is in Phase 2b trials for atopic dermatitis and asthma.</p><p>The company's business update also highlighted a strong financial position, with $1.6 billion in cash providing a runway into 2029, allowing it to fund operations beyond several key clinical milestones.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KYMR","symbol_name":"Kymera Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1123725701","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123725701","pubTimestamp":1772139313,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Kymera Therapeutics Inc. (KYMR) saw its stock price surge 5.04% during intraday trading on Thursday, marking a significant rebound in the session.The rally comes despite the company reporting a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KYMR":"Kymera Therapeutics, Inc."},"translate_title":"个股追踪|Kymera Therapeutics盘中飙升5.04%，尽管Q4未达预期，分析师仍维持看涨评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KYMR":1},"content_text":"Kymera Therapeutics Inc. (KYMR) saw its stock price surge 5.04% during intraday trading on Thursday, marking a significant rebound in the session.The rally comes despite the company reporting a wider-than-expected fourth-quarter net loss and revenue that fell short of analyst estimates. However, investor sentiment appeared buoyed by continued analyst confidence and positive updates on the company's clinical pipeline.Analysts at BTIG and Piper Sandler maintained their Buy and Overweight ratings on the stock, respectively, signaling ongoing belief in the company's long-term prospects. This support likely helped counter the negative initial reaction to the financial results. Furthermore, the company published a corporate presentation detailing progress in its pipeline of oral degrader medicines for immunology, including its lead STAT6 degrader, KT-621, which is in Phase 2b trials for atopic dermatitis and asthma.The company's business update also highlighted a strong financial position, with $1.6 billion in cash providing a runway into 2029, allowing it to fund operations beyond several key clinical milestones.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}